Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
60 Degrees Pharmaceuticals Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS
Ticker
Exchange
SIC #
Website
Latest Ticker
SXTP
Nasdaq
2834
https://60degreespharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for 60 Degrees Pharmaceuticals Inc
60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required
- May 2nd, 2024 11:59 am
60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis
- Apr 3rd, 2024 11:58 am
60 Degrees Pharmaceuticals Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
- Apr 3rd, 2024 11:14 am
60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024
- Mar 14th, 2024 11:59 am
60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris
- Feb 20th, 2024 12:59 pm
60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer
- Feb 8th, 2024 12:59 pm
WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
- Jan 31st, 2024 5:00 pm
60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering
- Jan 31st, 2024 4:15 pm
WallachBeth Capital Announces Pricing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering
- Jan 30th, 2024 2:45 pm
60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering
- Jan 30th, 2024 2:00 pm
60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting
- Jan 22nd, 2024 12:59 pm
60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements
- Jan 16th, 2024 12:59 pm
60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024
- Dec 26th, 2023 12:59 pm
60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease
- Nov 15th, 2023 12:29 pm
60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston
- Oct 19th, 2023 12:31 pm
60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases
- Oct 12th, 2023 8:16 pm
60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements
- Sep 18th, 2023 8:16 pm
60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference
- Sep 6th, 2023 11:31 am
Genetic Technologies Limited and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Money Report(R) on Bloomberg TV
- Sep 1st, 2023 1:00 pm
60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity
- Aug 30th, 2023 11:32 am
Scroll